» Articles » PMID: 34225791

Safety of SARS-CoV-2 Vaccines: a Systematic Review and Meta-analysis of Randomized Controlled Trials

Overview
Publisher Biomed Central
Date 2021 Jul 6
PMID 34225791
Citations 84
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Various modalities of vaccines against coronavirus disease 2019 (COVID-19), based on different platforms and immunization procedures, have been successively approved for marketing worldwide. A comprehensive review for clinical trials assessing the safety of COVID-19 vaccines is urgently needed to make an accurate judgment for mass vaccination.

Main Text: A systematic review and meta-analysis was conducted to determine the safety of COVID-19 vaccine candidates in randomized controlled trials (RCTs). Data search was performed in PubMed, Embase, Cochrane library, Scopus, Web of Science, and MedRxiv. Included articles were limited to RCTs on COVID-19 vaccines. A total of 73,633 subjects from 14 articles were included to compare the risks of adverse events following immunization (AEFI) after vaccinating different COVID-19 vaccines. Pooled risk ratios (RR) of total AEFI for inactivated vaccine, viral-vectored vaccine, and mRNA vaccine were 1.34 [95% confidence interval (CI) 1.11-1.61, P < 0.001], 1.65 (95% CI 1.31-2.07, P < 0.001), and 2.01 (95% CI 1.78-2.26, P < 0.001), respectively. No significant differences on local and systemic AEFI were found between the first dose and second dose. In addition, people aged ≤ 55 years were at significantly higher risk of AEFI than people aged ≥ 56 years, with a pooled RR of 1.25 (95% CI 1.15-1.35, P < 0.001).

Conclusions: The safety and tolerance of current COVID-19 vaccine candidates are acceptable for mass vaccination, with inactivated COVID-19 vaccines candidates having the lowest reported AEFI. Long-term surveillance of vaccine safety is required, especially among elderly people with underlying medical conditions.

Citing Articles

Self-Reported Adverse Events Following COVID-19 Vaccination Among Medical Sciences Students After a Symptomatology Training Program: A Cross-Sectional Study.

Tavanaei Tamanaei T, Oghazian M, Mojtabaee M, Faregh M, Oghazian S, Tavana E Health Sci Rep. 2025; 8(3):e70492.

PMID: 40041786 PMC: 11872685. DOI: 10.1002/hsr2.70492.


Serious adverse events following immunization and predictors of mortality associated with COVID-19 vaccination in India: a secondary data analysis of nationwide causality assessments.

Rajan A, Bashar M Ther Adv Vaccines Immunother. 2025; 13:25151355251321697.

PMID: 40034661 PMC: 11873861. DOI: 10.1177/25151355251321697.


Safety and Adverse Effects Related to COVID-19 Viral Vector Vaccines: A Systematic Review.

SeyedAlinaghi S, Pashaei A, Tantuoyir M, Karimi A, Mojdeganlou H, Nazarian N Tanaffos. 2025; 23(2):102-114.

PMID: 39959793 PMC: 11825072.


Predictors of moderate-to-severe side-effects following COVID-19 mRNA booster vaccination: a prospective cohort study among primary health care providers in Belgium.

Domen J, Abrams S, Digregorio M, Van Ngoc P, Duysburgh E, Scholtes B BMC Infect Dis. 2024; 24(1):1135.

PMID: 39390398 PMC: 11468363. DOI: 10.1186/s12879-024-09969-8.


A Response to: A Letter to the Editor Regarding 'Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework'.

Beck E, Bausch-Jurken M, Van de Velde N, Wang X, Malmenas M Infect Dis Ther. 2024; 13(10):2195-2202.

PMID: 39180646 PMC: 11416437. DOI: 10.1007/s40121-024-01020-2.


References
1.
Chen M, Li Y, Chen J, Wen Z, Feng F, Zou H . An online survey of the attitude and willingness of Chinese adults to receive COVID-19 vaccination. Hum Vaccin Immunother. 2021; 17(7):2279-2288. PMC: 8189089. DOI: 10.1080/21645515.2020.1853449. View

2.
Fulop T, Larbi A, Pawelec G . Human T cell aging and the impact of persistent viral infections. Front Immunol. 2013; 4:271. PMC: 3772506. DOI: 10.3389/fimmu.2013.00271. View

3.
Bhowmik E, Singh A, Sachan R . Profile of adverse events following immunization with measles rubella vaccine at a tertiary care hospital in East Delhi, India. Ther Adv Vaccines Immunother. 2020; 8:2515135520940131. PMC: 7343355. DOI: 10.1177/2515135520940131. View

4.
Mulligan M, Lyke K, Kitchin N, Absalon J, Gurtman A, Lockhart S . Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020; 586(7830):589-593. DOI: 10.1038/s41586-020-2639-4. View

5.
Zhu F, Guan X, Li Y, Huang J, Jiang T, Hou L . Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020; 396(10249):479-488. PMC: 7836858. DOI: 10.1016/S0140-6736(20)31605-6. View